A team of researchers from ICN2, the UAB and Bellvitge University Hospital has developed an adhesive membrane capable of killing up to 90% of cancer cells in laboratory models of glioblastoma, a particularly aggressive type of brain tumour. These findings pave the way for future studies in patients to assess its potential use in clinical practice.